SEC Form 4 · accession 0001179110-18-003126

ENDOCYTE INC · ECYT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Fred A Middleton

Director

Period of report

Feb 28, 2018

Accepted (ET)

Mar 1, 2018 · 4:27 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001235007

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F4,F1,F2	Feb 28, 2018	A	380,952	$4.20	A	1,212,413	I	By Sanderling Venture Partners VI Co-Investment Fund, L.P.
Common Stock^F4,F1,F2	Feb 28, 2018	A	119,048	$4.20	A	904,465	I	By Sanderling V Strategic Exit Fund, L.P.
Common Stock	holding	—	—		—	194,049	D
Common Stock^F1,F2	holding	—	—		—	1,017,304	I	By Sanderling Venture Partners V, L.P.
Common Stock^F1,F3	holding	—	—		—	267,491	I	By Sanderling Venture Partners V Co-Investment Fund, L.P.
Common Stock^F1,F2	holding	—	—		—	249,148	I	By Sanderling V Biomedical, L.P.
Common Stock^F1,F2	holding	—	—		—	162,170	I	By Sanderling V Biomedical Co-Investment Fund, L.P.
Common Stock^F1,F2	holding	—	—		—	113,315	I	By Sanderling V Limited Partnership
Common Stock^F1,F2	holding	—	—		—	100,828	I	By Sanderling V Beteiligungs GmbH & Co. KG
Common Stock^F1,F2	holding	—	—		—	10,049	I	By Sanderling VI Limited Partnership
Common Stock^F1,F2	holding	—	—		—	8,434	I	By Sanderling VI Beteiligungs GmbH & Co. KG

Table II — derivative securities

No Table II lines on this filing.

Explanation of responses

F1Mr. Middleton disclaims beneficial ownership of the shares directly held by the entities affiliated with Sanderling except to the extent of his individual pecuniary interest therein.
F2Fred Middleton is a managing director of Middleton, McNeil & Mills Associates V, LLC which has the ultimate voting and investment power over shares held of record by Sanderling V Beteiligungs GmbH & Co. KG, Sanderling V Biomedical Co-Investment Fund, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership, Sanderling Venture Partners V, L.P., Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH and Co. KG, Sanderling VI Limited Partnership and Sanderling V Strategic Exit Fund, L.P. and he may be deemed to have voting and investment power over shares held of record by Sanderling V Beteiligungs GmbH & Co. KG, Sanderling V Biomedical Co-Investment Fund, L.P., Sanderling V Biomedical, L.P., Sanderling V Limited Partnership, Sanderling Venture Partners V, L.P., Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH and Co. KG, Sanderling V Strategic Exit Fund, L.P. and Sanderling VI Limited Partnership.
F3Fred Middleton is a managing director of Middleton, McNeil & Mills Associate V, LLC which has the ultimate voting and investment power over shares held of record by Sanderling Venture Partners V Co-Investment Fund, L.P. and he may be deemed to have voting and investment power over shares held of record by Sanderling Venture Partners V Co-Investment Fund, L.P.
F4Represents shares purchased in conjunction with the Issuer's public offering on February 28, 2018.